Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and pegfilgrastim effects on circulating progenitor and tumor cells in metastatic breast cancer
ACTRN12607000221459Phase 2Recruiting
- Sponsor
- Royal Adelaide Hospital, Department of Medical Oncology
- Start
- May 2007
- Modality
- Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and pegfilgrastim in breast cancer, sponsored by Royal Adelaide Hospital, Department of Medical Oncology. Primary endpoints: Peak and duration of CD34+ progenitor cells in peripheral blood and Peak and duration of circulating tumor cells in peripheral blood. Started May 2007; status: recruiting.
02
Drugs
docetaxelpegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000221459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000221459.